Thursday, November 4, 2021 Daily Archives

Optimized Expression Systems for Increased Productivity in CHO DG44 Based Cell Line Development

by

This webcast features: Dr. Rathangadhara Nammalwar, Team Lead, Cell Line Development for Protein-Based Therapeutics, Sartorius The Global Cell Line Development (CLD) services market is growing at an unprecedented pace. In 2020, the global revenues were about $700 million and are estimated to reach nearly $1.7 billion by 2028. Chinese hamster ovary (CHO) cells have been the most preferred host cell line for those CLD services, and they alone generated more than 50% of the global revenue in 2020. Key success…

November 4, 2021

Bionova opens $25m single-use plant in Fremont

by

Bionova’s 2,000 L scale facility in Fremont, California marks a full transition to a contract development and manufacturing organization (CDMO) for the bioservices firm. In July 2020, Bionova broke ground on the $25 million Fremont facility with an aim to expand its protein, cell line, and process development services into the clinical and commercial manufacturing space. Fifteen months on and the company has officially opened the plant with the first clinical supply run expected to be completed before the end…

November 4, 2021

Catalent shows willing to up spending in CGT space

by

Catalent’s Q3 results revealed the demand for its CGT services means it is willing to increase its investments in the sector. Contract development manufacturing organization (CDMO) Catalent revealed plans in September 2020 to invest $130 million at its gene therapy campus in Harmans, Maryland to add five additional Phase III through to commercial-scale manufacturing suites. Last week, the firm said it would shell out a further $230 million at the same site to construct three additional multi-room commercial suites. While…

November 4, 2021

Spurred by CDMOs, global mammalian capacity to reach 7,500kL by 2025

by

According to a report, almost half (44%) of mammalian biomanufacturing capacity will be controlled by contract manufacturers or hybrid firms by 2025, a jump from 32% in 2020. The paper entitled ‘Supply and Demand Trends: Mammalian Biomanufacturing Industry Overview,’ produced by BioProcess Technology Group BDO, forms part of the CPhI Pharma Annual Report, published ahead of next week’s event in Milan, Italy. The authors Dawn Ecker and Patricia Seymour claim that the projected kilogram quantities of product needed to meet…

November 4, 2021

Vaccine partnership results in optimized mRNA process, says BioNet

by

BioNet’s product development of genetic vaccine know-how integrated with BIA’s chromatographic columns for mRNA purification has produced a high-yield mRNA process, says firm. BioNet is a French-Thai biotech firm that focuses on manufacturing genetically engineered vaccines and BIA Separations is a biochromatography development and manufacturing company, which Sartorius acquired in October 2020 for $423 million. The collaboration, which was formed in early 2021, has resulted in what the firms are calling a successful development of an optimized messenger RNA (mRNA)…

November 4, 2021